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Background. HER2/neu positive breast tumors are difficult to treat. About 25 to 30% of invasive breast
tumors overexpress the HER2/neu oncogene. These tumors are aggressive and become resistant to
chemotherapeutic drugs. 3,3′-diindolylmethane (DIM), the active metabolite of indole-3-carbinol, a
naturally occurring compound found in cruciferous vegetables, has been found to have anti-cancer
properties in both humans and animals. DIM has been shown to induce cell cycle arrest and apoptosis in
animal breast cancer models. Because HER2/neu overexpression confers resistance to paclitaxel, and DIM
has anti-tumor effects, we hypothesized that DIM will enhance the cytotoxic effects of paclitaxel, a
common taxane drug, on human Her2/neu breast cancer cells by potentiating its effect on cell cycle and
stimulating apoptosis.
Methods. The MDA-MB-435eB1 human Her2/neu breast cancer cells were treated with varying
concentrations of DIM and paclitaxel. The cells were analyzed at different time points (24, 48, and 72 h).
Proliferation was measured by a commercial cell proliferation assay (Promega Procheck Assay). Cell-cycle
analysis and apoptosis were determined by flow cytometry. Western blot analysis was performed on to
determine the effect of DIM and/or paclitaxel on the proteins involved in apoptosis, and epidermal growth
factor-induced activation of HER2/neu and ERK1/2 signaling proteins.
Results. Both DIM and paclitaxel exhibited time and concentration dependent inhibition of cell
proliferation. TUNEL assay indicated that the combination also increased the number of apoptotic cells
more than either agent alone. The presence of cleaved poly (ADPRibose) polymerase (PARP) significantly
increased in the combination treatment, whereas Bcl-2 is decreased. DIM alone decreased the activation of
the Her2/neu receptor; the combination decreased the activation of ERK1/ERK2.
Conclusions. DIM in combination with paclitaxel synergistically inhibits growth of Her2/neu human breast
cancer cells through G2M phase cell-cycle arrest and induction of apoptosis/necrosis. The Her2/neu
receptor and its downstream signaling protein ERK1/2 appear to be involved in DIM’s affect on cell
growth and differentiation, whereas apoptosis appears to be mediated through the mitochondrial pathway
(Bcl-2/ PARP). It appears DIM, a naturally occurring, nontoxic compound, may be a beneficial addition to
a traditional (taxane-based) chemotherapy regimen.
Key Words: breast cancer; HER2/neu; 3,3′-diindolylmethane; paclitaxel; apoptosis.

INTRODUCTION
Women with breast tumors that are positive for the HER2/neu gene are difficult to treat
[1, 2]. About 25 to 30% of all invasive breast tumors overexpress Her2/neu/erbB2 [1].
This gene increases the aggressiveness of breast cancer and resistance to
chemotherapeutic drugs, including paclitaxel (Taxol) and other taxanes [2–5].
Chemotherapeutic resistance leads to a high reoccurrence rate and ultimately affects

long-term survival. Attempts to improve chemosensitization of the HER2/neu positive
tumors to chemotherapeutic agents have met with limited success. Thus, there is a need to
develop treatment strategies that will enhance the effectiveness of these drugs for this
patient population.
Most tested strategies for improving chemotherapeutic effect involve combining
traditional chemotherapeutic agents in varying dose strengths, time courses, and drug
combinations. However, very rarely have non-traditional agents been used with more
traditional chemotherapies to study their effect. Numerous studies have demonstrated the
anti-cancer effects of food components such as quercetin, curcumin, and resveratrol
[6]. 3,3′-diindolylmethane (DIM) is a naturally occurring active component of cruciferous
vegetables that is formed from its precursor indole 3 carbinol (I3C). I3C and DIM have
been shown to protect against many neoplasms, including prostate, cervical, and breast
cancer [7–10]. In human breast cancer cells, I3C inhibits proliferation [11, 12], blocks
cells in the G1 phase of the cell cycle [21], and induces apoptosis [13]. I3C and
tamoxifen were found to act separately and/or cooperatively in inhibiting growth of
estrogen receptor positive cells [14]. Recently, DIM was also shown to decrease
proliferation of estrogen receptor-positive and estrogen receptor-negative breast cancer
cells by inducing a G1 cell cycle arrest [15] and by stimulating apoptosis [16]. DIM
induced apoptosis in breast cancer cells through the mitochrondrial pathway [17] by
inhibiting Akt and nuclear factor-_B pathway [17–20].
Studies have shown that HER2/neu overexpression in breast cancer cells confers
resistance to the mitotic effects of paclitaxel [21–24]. DIM induces cell death in breast
cancer cells. However, it is not known whether DIM can overcome the chemoresistance
of cancer cells. Therefore, we investigated whether DIM will enhance the cytotoxic
effects of paclitaxel by through alterations in ERK1/ERK2 signaling. In this study, we
used MDA-MB-435 human breast cancer cells transfected with HER2/neu/erbB2 (MDAMB-435eB1) to determine the individual and combined effects of DIM and paclitaxel on
cell growth, cell cycle, and apoptosis. We also investigated apoptotic pathways that may
be involved in the interactions of DIM and paclitaxel.

MATERIALS AND METHODS

Cell Culture
Dr. Dihua Yu at the University of Texas M.D. Anderson Cancer Center (Houston, TX)
kindly provided 435eb1 Her2/neu positive, estrogen/progesterone receptor negative
human breast carcinoma cells. Cells were grown in DMEM/F12 medium supplemented
with 10% fetal bovine serum (FBS). Every 4 weeks the cells were passaged with media
supplemented with G418 (800 ug/ml).

Materials
Bioresponse DIM was kindly provided by Dr. Michael Zeligs (BioResponse, LLC,
Boulder, CO). Polyclonal antibody to BCL-2, bax, and PARP were obtained from Santa
Cruz Biotechnology. Anti-ERK1/ERK2, and anti-phospho ERK1/ERK2 were obtained
from Cell Signaling.
Cell Survival Assay
435eb1 cells were plated in 96-well plates and incubated in DMEM/F12 with 5% FBS for
24 h. Cells were then treated with 0, 5, 10, and 15 uM DIM for 0, 24, 48, and 72 h. The
number of viable cells was determined with ProCheck cell viability assay.
Cell Cycle/Flow Cytometric Analysis
435eb1 cells were plated in T-175 flasks and incubated in DMEM/F12 with 5% FBS for
24 h. Cells were then treated with vehicle, 15 uM DIM, 10 nM Paclitaxel, and 15 uM
DIM +10 nM Paclitaxel and incubated for an additional 72 h. Attached and floating cells
were harvested, fixed in 70% ethanol, digested with RNase A, stained with propidium
iodide, and analyzed by fluorescence-activated cell sorting using a Beckman Coulter XLMCLTM flow cytometer with System II Software.
Apoptosis Assay
435eb1 cells were plated in T-175 flasks and incubated in DMEM/F12 with 5% FBS for
24 h. Cells were then treated with vehicle, 15 uM DIM, 10 nM Paclitaxel, and 15 uM
DIM +10 nM Paclitaxel and incubated for an additional 72 h. Cells were then harvested
and underwent TUNEL analysis using the ApopTag plus peroxidase in situ apoptosis
detection kit.
Western Blot Analysis
435eb1 cells were plated in T-75 flasks and incubated in DMEM/F12 with 10% FBS for
24 h. Cells were then treated with vehicle, 15 uM DIM, 10 nM Paclitaxel, and 15 uM
DIM +10 nM Paclitaxel and incubated for an additional 72 h. For determination of
HER2/neu, phospho-HER2/neu, ERK1/2, and phospho-ERK1/2, cells were incubated in
serum-free medium overnight and treated with DIM, paclitaxel, and the combination for
an additional 24 h before stimulation with epidermal growth factor for 15 min. Cells were
lysed and proteins extracted with cell lysis buffer (Cell Signaling). Proteins were
separated with SDS-PAGE and transferred to PVDF membrane. The membrane was
blocked with %0.4 casein (I-Block, Tropix) in PBS-T and then incubated with primary
antibodies overnight at 4°C. Blots were developed using a horseradish peroxidaseconjugated secondary antibody and proteins were visualized by enhanced
chemiluminescence (ECL), scanned with a densitometer (Sharp JX-330), quantitated by
Image Master 1D, and expressed as arbitrary units relative to the control (β-actin).

Statistical Analysis
Cell survival and apoptosis data were analyzed using simple linear regression (equivalent
to two-way ANOVA) to compare the groups.

RESULTS
Effects of DIM on Cell Growth
DIM alone had both a time and concentration dependent effect on cell growth. After 72
h; 5 uM DIM decreased cell growth by 23% (SEM ±1.08%), 10 uM DIM decreased cell
growth by 28% (+/- 1.31%), and 15 uM DIM decreased cell growth by 34% (±2.27%) in
comparison to control (P < 0.001) (Fig. 1).

FIG. 1. Increasing concentrations of DIM inhibit cell growth in human breast carcinoma 435 eb1
cells (Her2/neu positive). Cells were plated in 96-well plates, incubated for 24 h and then treated
with 0, 5, 10, and 15 uM DIM for 0, 24, 48, and 72 h. The number of viable cells was determined
with ProCheck cell viability assay. Values represent mean ±SEM.

Effects of DIM and Paclitaxel on Cell Growth
DIM and paclitaxel together significantly decreased cell growth when compared to
control or either treatment alone. After 72 h of incubation, cell growth was inhibited by
15 uM DIM, 10 nM paclitaxel and the combination of the two treatments by 42%
(±3.26%), 62%(±1.12%), and 74% (±1.07%), respectively (P < 0.001) (Fig. 2).

FIG. 2. DIM in combination with paclitaxel inhibits cell growth in human breast carcinoma 435
eb1 cells (Her2/neu positive). Cells were plated in 96-well plates, incubated for 24 h and then
treated with vehicle, 10 uM DIM, 15 uM DIM, 10 nM paclitaxel, 10 uM DIM +10 nM paclitaxel,
and 15 uM DIM +10 nM paclitaxel for 0, 24, 48, and 72 h. The number of viable cells was
determined with ProCheck cell viability assay. Values represent mean ± SEM.

Effects of DIM and Paclitaxel on Cell Cycle
After treatment with 15 uM DIM and 10 nM paclitaxel in a starvation media (5% FBS), a
small, but not significant increase was seen in the number of cells in the G2M phase of
the cell cycle (Fig. 3).

FIG. 3. DIM in combination with paclitaxel induces G2/M cell cycle phase arrest. Cells were
plated in T-175 flasks, incubated for 24 h and then treated with vehicle, 15 uM DIM, 10 nM
paclitaxel, and 15 uM DIM _10 nM paclitaxel and incubated for an additional 72 h. Cells were
then harvested and underwent cell cycle analysis by flow cytometry.

Effects of DIM and Paclitaxel on Aapoptosis
The combination of DIM and paclitaxel synergistically increased apoptosis, detected by
the TUNEL assay, a measure of DNA fragmentation. The combined treatment induced
apoptosis in 34.8% of treated cells. The percentage of apoptotic cells was increased in
435 eb1 cells treated with DIM and paclitaxel compared with vehicle-treated cells
(control 1.82%, DIM 6.59%, paclitaxel 7.39%) (Fig. 4).

FIG. 4. DIM in combination with paclitaxel increases apoptosis. Cells were plated in T-175
flasks, incubated for 24 h and then treated with vehicle, 15 uM DIM, 10 nM paclitaxel, and 15 uM
DIM +10 nM paclitaxel and incubated for an additional 72 h. Cells were then harvested and
underwent TUNEL analysis.

Effects of DIM and Paclitaxel on Apoptosis-Related Protein Expression
Protein expression of cleaved poly (ADP-Ribose) polymerase (PARP), an early marker of
apoptosis, was up regulated in cells treated with DIM and paclitaxel. Up-regulation was
synergistically increased by the combination of the two compounds (Fig. 5A).
Expression of the protein, BCL-2, an inhibitor of apoptosis, was significantly reduced in
samples treated with DIM and paclitaxel. Paclitaxel’s effect on the proapoptotic protein,
Bax, was not altered by the addition of DIM (Fig. 5B).
Effects of DIM and Paclitaxel on Phosphorylation
of HER-2/Neu/EGFR and ERK1/2
DIM, paclitaxel, and the combined treatment decreased phosphorylation of the Her2/neu
receptor (Fig. 6A). We have not measure whether HER3 and HER-4 are present in these
cells. There does appear to be an additive/synergistic effect when the two agents are
combined.

However, the protein expression of ERK1/2 and phosph-ERK1/2 decreased in cells
treated with DIM and paclitaxel and paclitaxel alone. The combination super-additively
inhibited the activation of ERK1/ERK2.

FIG. 5. DIM in combination with paclitaxel down-regulates BCL-2 expression. However, it
appears to have little effect on Bax expression. PARP cleavage and activation is also increased by
the treatments. Cells were plated in T-75 flasks, incubated for 24 h and then treated with vehicle,
15 uM DIM, 10 nM paclitaxel, and 15 uM DIM +10 nM paclitaxel and incubated for an additional
72 h. Cells were then lysed, the proteins were extracted, and Western blot analysis was performed.

FIG. 6. DIM in combination with paclitaxel down-regulates Her2/neu and ERK1/ERK2
phosphorylation and activation. Cells were plated in T-75 flasks, incubated for 24 h in 5%
(starving) media and then treated with vehicle, 15 uM DIM, 10 nM paclitaxel and 15 uM DIM +10
nM paclitaxel and incubated for an additional 24 h. Cells were then lysed, the proteins were
extracted, and Western blot analysis was performed.

DISCUSSION
DIM and I3C have anticancer effects specifically through cell cycle arrest [7, 12, 14],
apoptosis [17–19] as well as NF-κB, akt [18, 19], and Bax inhibition [17]. Paclitaxel’s
effects are mediated by inhibiting microtubule formation [3]. Each of these compounds
are effective against breast cancer cells with clearly distinct mechanisms of action.
Compounds similar to DIM, such as resveratrol have been shown to enhance the effects
of paclitaxel on lung cancer cell lines [6]. In this study we demonstrate for the first time

that enhances the cytotoxicity of paclitaxel in a breast cancer cell line with
overexpression of HER2/neu.
The combined treatments induced a greater apoptotic effect than either treatment alone.
Several pathways leading to apoptosis converge at the mitochrondrial membrane; the
breakdown of the mitochrondrial membrane is controlled, in part, by the balance of Bcl2
and Bax in cells. The protein expression of Bcl2 decreased in cells treated with DIM
alone or the combination of DIM + paclitaxel, whereas there was no change in Bax
protein expression. Thus, the ratio of Bax to Bcl2 was altered in favor of apoptosis.
Studies using Her2/neu negative breast cancer cell lines have also shown an effect on the
Bax/Bcl2 ratio by paclitaxel and DIM [25, 26]. Cleaved PARP, an early marker of
apoptosis, is formed in significantly greater amounts with the combined treatment than
with either treatment alone (Fig. 5A) [27]. Interestingly, we found no effect of DIM on
Bax protein in these cells, an effect previously described in other cell lines [17].
However, the concentrations of DIM were as much as ten times higher than those used in
our study.
Importantly, we observed that DIM decreased the phosphorylation of HER2. Because
HER2/neu expression confers resistance to the taxanes, DIM may improve the response
of the 435-eb cells to paclitaxel by down-regulating HER2. Studies have shown that
combining paclitaxel with Herceptin improved the response of resistant HER2/neu
overexpressing breast cancer cells to the taxanes [26, 27]. The observation that a nontoxic
nutrient like DIM that is found in foods may block HER2 signaling may offer clinical
advantages. Current therapeutic protocols use the taxanes in combination with Herceptin.
However, Herceptin is associated with cardiotoxic effects [28] that may be minimized by
use of DIM. Recent studies have demonstrated that DIM down-regulates the MAPK
pathway [29]. In this study we demonstrated that ERK1/ERK2 is inhibited more by the
combination therapy than with either treatment alone. This result suggests that paclitaxel
may be acting on one of the upstream proteins in the ERK1/ERK2 pathway. In fact, DIM
has been shown to down-regulate Ras signaling, which is upstream of MAPK [30]. It is
often the case in cell culture experiments that high concentrations of the agent must be
used to achieve cytoxic effects. In this study the concentration of DIM (15 _M) found to
enhance the effectiveness of paclitaxel and alter signaling corresponds to the plasma level
of humans taking dietary supplements [31].
In summary, DIM appears to significantly enhance the cytotoxicity of paclitaxel in the
435eb1 Her2/neu positive, ER/PR negative breast cancer cell line—a cell line known to
be particularly resistant to taxane treatment both in vitro and in vivo. This effect is
produced primarily through the up-regulation of apoptosis in the cells treated with a
combination of DIM and paclitaxel. Further study into the mechanism of this effect is
necessary to pinpoint the precise proteins regulated by these compounds and confirm the
two distinct implicated in this study. In vivo studies will be necessary to confirm not only
the effectiveness of this combination treatment, but also to evaluate any additional
cytotoxicity against normal cells. These early studies do suggest that DIM may possibly
be used clinically as a chemosensitizing agent with taxanes in treatment of traditionally
taxane-resistant tumors [32,33].
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